EHA 2021 | Sabatolimab plus HMAs in patients with HR-MDS and AML
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the findings of a subgroup analysis of a Phase I trial (NCT03066648) investigating sabatolimab, a novel TIM-3 inhibitor, plus hypomethylating agents (HMAs) for patients with high-risk or very high-risk (HR/vHR) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Prof Wei discusses the mechanism of action of sabatolimab and highlights key findings from the study. 23% of patients who received sabatolimab plus HMAs were able to undergo allogeneic stem cell transplantation, with no evidence of treatment-related complications. Prof. Wei reports that the combination was well-tolerated and demonstrated an overall response rate of 58% in patients with HR-MDS. Prof. Wei also discusses the impact of molecular features such as TP53 on efficacy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew Wei, MBBS, PhD, has received research grants from Abbvie, Amgen, AstraZeneca, Celgene/BMS, Novartis, Servier and F. Hoffmann-La Roche; has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in speakers bureau for Novartis, Abbvie and Celgene/BMS, has participated in consultancy work for Servier; is a former employee of the Walter and Eliza Hall Institute, and is eligible for a fraction of the royalty stream related to Venetoclax.
